Hosey Chelsea M, Broccatelli Fabio, Benet Leslie Z
Department of Bioengineering and Therapeutic Sciences, University of California, 533 Parnassus Ave., Room U-68, San Francisco, California, 94143-0912, USA.
AAPS J. 2014 Sep;16(5):1085-96. doi: 10.1208/s12248-014-9636-1. Epub 2014 Jul 9.
Biliary excretion is an important route of elimination for many drugs, yet measuring the extent of biliary elimination is difficult, invasive, and variable. Biliary elimination has been quantified for few drugs with a limited number of subjects, who are often diseased patients. An accurate prediction of which drugs or new molecular entities are significantly eliminated in the bile may predict potential drug-drug interactions, pharmacokinetics, and toxicities. The Biopharmaceutics Drug Disposition Classification System (BDDCS) characterizes significant routes of drug elimination, identifies potential transporter effects, and is useful in understanding drug-drug interactions. Class 1 and 2 drugs are primarily eliminated in humans via metabolism and will not exhibit significant biliary excretion of parent compound. In contrast, class 3 and 4 drugs are primarily excreted unchanged in the urine or bile. Here, we characterize the significant elimination route of 105 orally administered class 3 and 4 drugs. We introduce and validate a novel model, predicting significant biliary elimination using a simple classification scheme. The model is accurate for 83% of 30 drugs collected after model development. The model corroborates the observation that biliarily eliminated drugs have high molecular weights, while demonstrating the necessity of considering route of administration and extent of metabolism when predicting biliary excretion. Interestingly, a predictor of potential metabolism significantly improves predictions of major elimination routes of poorly metabolized drugs. This model successfully predicts the major elimination route for poorly permeable/poorly metabolized drugs and may be applied prior to human dosing.
胆汁排泄是许多药物的重要消除途径,但测量胆汁消除的程度困难、具有侵入性且存在变异性。对于少数药物,在受试者数量有限(且这些受试者通常为患病患者)的情况下对胆汁消除进行了定量。准确预测哪些药物或新分子实体在胆汁中被显著消除,可能有助于预测潜在的药物相互作用、药代动力学和毒性。生物药剂学药物处置分类系统(BDDCS)可表征药物消除的主要途径,识别潜在的转运体效应,有助于理解药物相互作用。1类和2类药物在人体内主要通过代谢消除,母体化合物不会有显著的胆汁排泄。相比之下,3类和4类药物主要以原形经尿液或胆汁排泄。在此,我们表征了105种口服3类和4类药物的主要消除途径。我们引入并验证了一种新型模型,该模型使用简单的分类方案预测显著的胆汁消除。对于模型开发后收集的30种药物,该模型的准确率为83%。该模型证实了胆汁消除药物具有高分子量这一观察结果,同时表明在预测胆汁排泄时考虑给药途径和代谢程度的必要性。有趣的是,潜在代谢的预测指标可显著改善对代谢不良药物主要消除途径的预测。该模型成功预测了低渗透性/低代谢性药物的主要消除途径,可在人体给药前应用。